Clinical status, quality of life, and work productivity in Crohn’s disease patients after one year of treatment with adalimumab

  1. Cristina Saro Gismera 1
  2. Daniel Ceballos Santos 2
  3. Fernando Muñoz 3
  4. Cristóbal de la Coba 1
  5. María Dolores Aguilar 4
  6. Pablo Lázaro de Mercado
  7. Valle García Sánchez 5
  8. Mariola Hernández 6
  9. Jesús Barrio Andrés 7
  10. Ruth de Francisco 8
  11. Luis Ignacio Fernández Salazar 9
  12. Manuel Barreiro de Acosta 10
  1. 1 Hospital Cabueñes. Gijón, Spain
  2. 2 Hospital Dr. Negrín. Las Palmas, Spain
  3. 3 Hospital de Salamanca. Salamanca, Spain
  4. 4 Advanced Techniques in Health Services Research. Madrid, Spain
  5. 5 Hospital Universitario Reina Sofía. Córdoba . Spain
  6. 6 Hospital Virgen del Puerto. Plasencia, Spain
  7. 7 Hospital Universitario Río Hortega. Valladolid. Spain
  8. 8 Hospital Universitario Central de Asturias. Oviedo, Spain
  9. 9 Hospital Clínico Universitario de Valladolid. Valladolid, Spain
  10. 10 Complexo Hospitalario Universitario de Santiago
    info

    Complexo Hospitalario Universitario de Santiago

    Santiago de Compostela, España

    ROR https://ror.org/00mpdg388

Montrer des affiliations +
Revue:
Revista Española de Enfermedades Digestivas

ISSN: 2340-416,  1130-0108

Année de publication: 2017

Volumen: 109

Número: 2

Pages: 122-129

Type: Article

DIALNET GOOGLE SCHOLAR

D'autres publications dans: Revista Española de Enfermedades Digestivas

Résumé

Objective: Clinical trials have shown the efficacy of adalimumab in Crohn’s disease, but the outcome in regular practice remains unknown. The aim of the study was to examine clinical status, quality of life, and work productivity of Crohn’s disease patients receiving adalimumab for one year in the context of usual clinical practice. Material and methods: This was a prospective, observational study with a one-year follow-up. After baseline, Crohn’s disease patients were evaluated at 1, 3, 6, 9, and 12 months after starting treatment with adalimumab. Outcome variables included: clinical status (measured with CDAI), quality of life (measured with EuroQoL-5D and IBDQ), and work productivity (measured with WPAI questionnaire). These outcome variables were compared using the Student’s t test or Wilcoxon test for paired comparison data according to the data distribution. Statistical significance was set at two-sided p < 0.05. Results: The sample was composed of 126 patients (age [mean] 39.1 ± [standard deviation] 13.8 years; 51% male). Significant changes were observed during the follow-up period: CDAI decreased from [median] 194 ([25-75 percentiles] 121-269) to 48.2 (10.1-122.0) (p < 0.05); the EuroQoL-5D increased from 0.735 (0.633-0.790) to 0.797 (0.726-1.000) (p < 0.05); the EuroQoL- 5D visual analogue scale increased from 50.0 (40-70) to 80.0 (60- 90); (p < 0.05) and the IBDQ increased from 56.7 (51.6-61.5) to 67.5 (60.1-73.6) (p < 0.05). The total work productivity impact decreased from 53% to 24% (p < 0.05). Conclusions: In regular practice, adalimumab is clinically effective in the treatment of Crohn’s disease patients and results in a significant improvement in quality of life and work productivity.

La source de données: Dialnet